Illumina Inc - Company Profile
Powered by 
All the data and insights you need on Illumina Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Illumina Inc Strategy Report
- Understand Illumina Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and cancer. The company’s portfolio encompasses sequencing kits and reagents; sequencing tools and systems; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; instrument services, training, and consulting. The company serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Illumina is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
5200 Illumina Way, San Diego, California, 92122-4616
Website
www.illumina.com
Telephone
1 858 2024500
No of Employees
10,590
Industry
Medical Equipment
Ticker Symbol & Exchange
ILMN (NASD)
Revenue (2022)
$4.5B
-1.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
73.6%
(2022 vs 2021)
Market Cap*
$18.2B
Net Profit Margin (2022)
XYZ
73.2%
(2022 vs 2021)
* As of and is in US$
Illumina Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Instruments: | Consulting Services | Illumina |
| Sequencing Platforms | Instrument Services | Assign |
| Microarray Scanners | Sequencing Services | Ampligase |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In May, the company and Garvan Institute jointly invest in single-cell disease research. |
| 2024 | Divestiture | In April, the company announced it had received approval for its divestment plan for GRAIL from the European Commission (EC). |
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Janssen Research & Development, LLC to collaborate on the advancement of Illumina's innovative molecular residual disease assay. |
Competitor Comparison
| Key Parameters | Illumina Inc | Thermo Fisher Scientific Inc | Agilent Technologies Inc | Qiagen NV | Oxford Nanopore Technologies Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Netherlands | United Kingdom |
| City | San Diego | Waltham | Santa Clara | Venlo | Oxford |
| State/Province | California | Massachusetts | California | - | England |
| No. of Employees | 10,590 | 122,000 | 17,700 | 5,967 | 1,238 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephen P. MacMillan | Chairman | Executive Board | 2023 | 60 |
| Jacob Thaysen, Ph.D | Chief Executive Officer; Director | Executive Board | 2023 | 48 |
| Ankur Dhingra | Chief Financial Officer | Senior Management | 2024 | - |
| Jakob Wedel | Chief Corporate Development Officer; Chief Strategy Officer | Senior Management | 2024 | - |
| Carissa Rollins | Chief Information Officer | Senior Management | 2022 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer